AC Immune (ACIU) EBITDA (2015 - 2026)

AC Immune (ACIU) has 12 years of EBITDA data on file, last reported at -$18.9 million in Q1 2026.

• On a quarterly basis, EBITDA rose 12.35% year-over-year to -$18.9 million in Q1 2026; TTM through Mar 2026 was -$80.5 million, a 39.83% decrease from a year earlier, with the FY2025 full-year figure at -$83.6 million, down 39.83% from the prior year.
• EBITDA for Q1 2026 stood at -$18.9 million, down from -$18.0 million in the prior quarter.
• Over the last five years, EBITDA for ACIU reached as high as $8.4 million in Q3 2024 and fell as low as -$23.4 million in Q2 2025.
• Historically, EBITDA has averaged -$17.3 million across 5 years, with a median of -$19.4 million in 2022.
• On a YoY basis, EBITDA climbed as much as 147.92% in 2024 and fell as far as 432.39% in 2024.
• Year by year, EBITDA stood at -$19.4 million in 2022, then surged by 79.43% to -$4.0 million in 2023, then tumbled by 432.39% to -$21.3 million in 2024, then increased by 15.26% to -$18.0 million in 2025, then fell by 4.86% to -$18.9 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$18.9 million in Q1 2026, -$18.0 million in Q4 2025, and -$20.2 million in Q3 2025.